| 產(chǎn)品名稱 |
20H11 |
| 商品貨號(hào) |
B163640 |
| Organism |
Homo sapiens, human |
| Tissue |
spleen |
| Cell Type |
B lymphocyte; Epstein-Barr virus (EBV) transformed |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 Cells Contain HERPESVIRUS
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts with P aeruginosa Fisher immunotypes 2, 6 and 7. The antibody cross-reacts extensively with clinical isolates of P. aeruginosa bearng type b flagella. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Clinical Data |
Peripheral blood B cells from a patient immunized with high molecular weight polysaccharide from P. aeruginosa were transformed with Epstein-Barr virus. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa (flagella type b) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa (flagella type b) |
| Comments |
Peripheral blood B cells from a patient immunized with high molecular weight polysaccharide from P. aeruginosa were transformed with Epstein-Barr virus. The antibody reacts with P aeruginosa Fisher immunotypes 2, 6 and 7. The antibody cross-reacts extensively with clinical isolates of P. aeruginosa bearng type b flagella. |
| Complete Growth Medium |
Iscove's modified Dulbecco's medium with 2 mM L-glutamine, 85%; heat-inactivated fetal bovine serum, 15%
|
| Subculturing |
Medium Renewal: Every 3 to 4 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Population Doubling Time |
24 to 36 hrs |
| Name of Depositor |
Genetic Systems Corp. |
| Deposited As |
Homo sapiens |
| U.S. Patent Number |
|
| References |
Rosok MJ, Lostrom ME. Monoclonal antibodies to Pseudomonas aeruginosa flagella. US Patent 4,834,976 dated May 30 1989
|
